Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question
- 15 July 2009
- journal article
- editorial
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 11 (7) , 408-410
Abstract
No abstract availableThis publication has 38 references indexed in Scilit:
- Editorial: on the road to multi-modal and pluri-disciplinary treatment of glioblastomasActa Neurochirurgica, 2009
- The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drugInvestigational New Drugs, 2009
- Hypoxia- and Vascular Endothelial Growth Factor-Induced Stromal Cell-Derived Factor-1α/CXCR4 Expression in GlioblastomasThe American Journal of Pathology, 2008
- Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and AngiogenesisJournal of Clinical Oncology, 2008
- Cerebellar Glioblastoma Multiforme in an AdultJournal of Korean Neurosurgical Society, 2008
- A histologically derived stereotaxic atlas and substance P immunohistochemistry in the brain of the least shrew (Cryptotis parva) support its role as a model organism for behavioral and pharmacological researchBrain Research, 2007
- Substance P receptor in U373 MG human astrocytoma cells activates mitogen-activated protein kinases ERK1/2 through SrcBrain Tumor Pathology, 2005
- Ontogeny of substance P-immunoreactive structures in the primate cerebral neocortexDevelopmental Brain Research, 1990
- Ontogeny of glutamic acid decarboxylase, tyrosine hydroxylase, choline acetyltransferase, somatostatin and substance P in monkey cerebellumDevelopmental Brain Research, 1987
- Glioblastoma multiforme of the cerebellum: Description of three casesActa Neurochirurgica, 1980